Morning Notes : VPK NA, MAAT FP, ZEAL DC

: VPK NA, MAAT FP, ZEAL DC

MaaT Pharma Business update highlights upcoming priorities, final ARES...

MaaT provides a business update, which reiterated the company's progress with respect to its pipeline, and following the previously announced EU regulatory submission for MaaT013 in aGvHD, the company continues to search for a commercialisation partner in Europe ahead of a potential approval in 2H26. Timeline for MaaT013 US trial launch shifts to 2026 (from 4Q25) to focus resources on the European opportunity. Looking ahead, data updates for MaaT013 in aGvHD (final results incl. 12-month OS), as...

Utilities and offshore wind supply chain sector/Mind the gaps

In this report we present our view on the long-term growth prospects for offshore wind in Europe, implications of the energy transition and the role of TSOs, such as Elia Group. We also focus on supply chain beneficiaries in our Benelux coverage. An increasing number of long-term framework contracts should provide improved risk-rewards to the supply chain, in our view. Furthermore, we take a deep dive into growth drivers and long-term financing for Elia Group, beyond the company's current financ...

MaaT Pharma Updated MaaT013 aGvHD EAP data at EHA shows consistent out...

MaaT reported updated early access program (EAP) results for MaaT013 (microbiome therapy, enema formulation) in aGvHD at EHA, being held 12-15 June. The data, which was previously shared in the abstract last month, shows that the response rates and overall survival observed in the steroid refractory and ruxulitinib resistant subset of patients (n=70) are in line with what was observed in the phase 3 ARES trial. In our view, this points to the consistency of outcomes with MaaT013 in this patient ...

Morning Notes : AGFB BB, BPOST BB, GLPG NA, PROX BB, UCB BB, MAAT FP

: AGFB BB, BPOST BB, GLPG NA, PROX BB, UCB BB, MAAT FP

MaaT Pharma Completes EU regulatory submission for MaaT013 in aGvHD

MaaT announced the submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead drug candidate MaaT013 (microbiome therapy, enema formulation) in aGvHD under the brand name Xervyteg. Potential approval could be granted in 2H26, and MaaT is actively exploring strategic partnerships to commercialise MaaT013 in Europe. We believe the solid phase 3 results and good uptake in the early access program will be supportive of MaaT013's commercial launch ...

Morning Notes : AED BB, BPOSTb BB, FLOB BB, MAAT FP, PHVS US

: AED BB, BPOSTb BB, FLOB BB, MAAT FP, PHVS US

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 05/26/2025

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 05/26/2025

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 26/05/2025

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 26/05/2025

ODDO : Feedback Benelux Conference 2025

On Wednesday 21 May we hosted our 30th ABN AMRO – ODDO BHF Benelux Forum at ABN AMRO’s headquarters. The forum was attended by 21 listed companies (almost all C-level attendance) and around 70 investors. We hosted roughly 300 meetings overall.

Morning Notes : CPINV BB, DIE BB, ENX FP, MDXH BB, ALFEN NA, SYENS BB

: CPINV BB, DIE BB, ENX FP, MDXH BB, ALFEN NA, SYENS BB

EHA abstracts Autolus, Galapagos, MaaT

The abstracts for presentations at EHA (12-15 June) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (long-term findings and predictors of sustained remission for Aucatzyl in r/r adult ALL, as well as age stratified outcomes), Galapagos (more data and follow up from its decentralised CAR-T program) and MaaT (additional data from ...

Alfen A growth company that doesn't grow

In this note we adjust our estimates as Alfen's 1Q25 results have once again fallen short of expectations. The outlook for the smart grid solutions segment, which was anticipated to be robust, disappointed. Despite investment plans highlighting labour shortages, the impact has been more severe than anticipated. Additionally, gross profit margins dynamics in the smart grid segment are well below our expectations. In the EV charging segment, public demand was low, while increased competition in th...

Morning Notes : ABN NA, AGFB BB, BEKB BB, COFB BB, DIE BB, SHUR BB, MA...

: ABN NA, AGFB BB, BEKB BB, COFB BB, DIE BB, SHUR BB, MAAT FP, DEME BB, PHVS US

MaaT Pharma 1Q25 reiterates pipeline timelines, cash runway into Octob...

MaaT reported 1Q25 results with revenues of € 1.1m (1Q24 € 0.8m), and a cash position of € 24.4m (YE24: € 20.2m), which provides a cash runway into October 2025. Pipeline timelines were reiterated and we look forward to phase 2 data for MaaT013 in combination with immune checkpoint inhibitors in metastatic melanoma in 2H25, and hope to learn more about the company's progress with respect to partnering discussions for MaaT013 in aGvHD in Europe as we approach MAA submission in June 2025. We reite...

Alfen/Less appealing than we thought/HOLD (previously Buy)

Alfen has lowered both its FY25 revenue and adjusted EBITDA margin guidance. We cut our FY25F EBITDA estimate by 39%. Our old forecasts aimed at the mid-point of the former revenue guidance and we now aim at the low end of the new revenue guidance. With regards to the adjusted EBITDA margin guidance we aim below the low end of the new guidance as the gross margin mix works against Alfen. We change our recommendation from Buy to HOLD. The two ingredients for our prior bullish view were: (1) Posit...

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 05/13/2025

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 13/05/2025